EichorEICHOR
Location: Lakewood Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Lakewood

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Phase N/A · Congenital Muscle Disease International Registry (www.cmdir. · Cure CMD · NCT01403402
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Monmouth Medical Center Southern Campus · NRG Oncology · NCT05624996
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2 · Rocky Mountain Gastroenterology Associates - Lakewood · Eli Lilly and Company · NCT07415044
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · CommonSpirit Saint Anthony Hospital Cancer Center · Alliance for Clinical Trials in Oncology · NCT07091617
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Phase N/A · Colorado Retina Associates, PLLC · Astellas Pharma Global Development, Inc. · NCT06779773
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Phase N/A · Rocky Mountain Cancer Center - Lakewood · Agendia · NCT03053193
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Rocky Mountain Cancer Centers LLP · Pfizer · NCT07144280
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Phase 2 · Colorado Urology · Zenith Epigenetics · NCT04986423
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2 · Colorado Urology · CG Oncology, Inc. · NCT06567743
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · CommonSpirit Saint Anthony Hospital Cancer Center · NRG Oncology · NCT05174169
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate
Phase 3 · Teva Investigational Site 12142 · Teva Branded Pharmaceutical Products R&D LLC · NCT06664619
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · CommonSpirit Saint Anthony Hospital Cancer Center · Alliance for Clinical Trials in Oncology · NCT06632327
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
NA · Vivage/Beecan Corporation · University of Alabama, Tuscaloosa · NCT05820919
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
Phase N/A · Arthur F Gelb MD · Gelb, Arthur F., M.D. · NCT03263130
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Colorado Clinical Research · Janssen Research & Development, LLC · NCT06319820
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · CommonSpirit Saint Anthony Hospital Cancer Center · Alliance for Clinical Trials in Oncology · NCT06876714
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder
Phase 2 · Advanced Urology · Protara Therapeutics · NCT05951179
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · CommonSpirit Saint Anthony Hospital Cancer Center · National Cancer Institute (NCI) · NCT04269902
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · CommonSpirit Saint Anthony Hospital Cancer Center · Canadian Cancer Trials Group · NCT06592924
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO
Phase 3 · GSK Investigational Site · GlaxoSmithKline · NCT07177339
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene M
Phase 2 · Saint Anthony Hospital · SWOG Cancer Research Network · NCT05806515
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Phase 2 · Colorado Urology · Dendreon · NCT06134232
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Phase 2 · RWJBarnabas Health - Monmouth Medical Center Southern Campus · Rutgers, The State University of New Jersey · NCT05332002
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · CommonSpirit Saint Anthony Hospital Cancer Center · Alliance for Clinical Trials in Oncology · NCT04242095
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
Phase 4 · Colorado Retina · Neurotech Pharmaceuticals · NCT06971939
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Monmouth Medical Center Southern Campus · National Cancer Institute (NCI) · NCT05256225
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Rocky Mountain Cancer Centers-Lakewood · Eastern Cooperative Oncology Group · NCT05108298
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Monmouth Medical Center Southern Campus · NRG Oncology · NCT05327686
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Rocky Mountain Cancer Centers, LLP · Pfizer · NCT07222800
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Saint Anthony Hospital · ECOG-ACRIN Cancer Research Group · NCT04566328
Look up another city
Look up another condition